home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

26.46 -0.32 (-1.19%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

3 Reasons Why Amphastar Is a Great Growth Stock ↗

December 26, 2023

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great...

Via Talk Markets

3 Stocks at the Forefront of Medical Innovation ↗

December 25, 2023

Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way.

Via InvestorPlace

Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade ↗

December 21, 2023

On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84.

Via Investor's Business Daily

Why NASDAQ:AMPH qualifies as a high growth stock. ↗

December 12, 2023

Why the growth investor may take a look at AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH).

Via Chartmill

TG Therapeutics Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating ↗

December 07, 2023

TG Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 87 to 93.

Via Investor's Business Daily

Exploring NASDAQ:AMPH's CANSLIM characteristics. ↗

December 05, 2023

Should you consider AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) for growth investing?

Via Chartmill

Exploring growth characteristics of AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH). ↗

November 21, 2023

Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock.

Via Chartmill

Evaluating NASDAQ:AMPH for Growth Investment Opportunities. ↗

November 14, 2023

High growth, ROE and relative strength for AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH), growth investors may appreciate this.

Via Chartmill

Recap: Amphastar Pharma Q3 Earnings ↗

November 08, 2023

Via Benzinga

These Three Biotech Stocks Are Trading At A Discount ↗

November 23, 2023

Investors exposed to the biotech sector have seen mixed results this year.

Via Talk Markets

Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

November 20, 2023

Via ACCESSWIRE

Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade ↗

November 10, 2023

Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before.

Via Investor's Business Daily

Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

November 09, 2023

Via ACCESSWIRE

7 Healthcare Stocks That Are Poised to Become the Next Unicorns ↗

November 09, 2023

Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments.

Via InvestorPlace

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023

November 08, 2023

Via ACCESSWIRE

Earnings Preview For Amphastar Pharma ↗

November 07, 2023

Via Benzinga

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023

August 08, 2023

Via ACCESSWIRE

Disney, Twilio, TransDigm, Marathon Digital And Other Big Stocks Moving Higher On Thursday ↗

November 09, 2023

U.S. stocks traded mostly lower, with the Dow Jones falling around 75 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade ↗

November 08, 2023

On Wednesday, CRISPR Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85, up from 68 a day earlier.

Via Investor's Business Daily

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2023

November 01, 2023

Via ACCESSWIRE

Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90 ↗

October 31, 2023

Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90 ↗

October 16, 2023

Revolution Medicines shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating ↗

September 27, 2023

A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.

Via Investor's Business Daily

Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes

September 13, 2023

Via ACCESSWIRE

12 Health Care Stocks Moving In Monday's After-Market Session ↗

September 11, 2023

Via Benzinga

Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes

September 11, 2023

Via ACCESSWIRE

Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

September 12, 2023

Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock.

Via Benzinga

Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference

August 31, 2023

Via ACCESSWIRE

Eli Lilly (LLY) Stock Up Almost 50% Year to Date: Here's Why ↗

August 17, 2023

Eli Lilly and Company (LLY) boasts a solid portfolio of core drugs in diabetes, autoimmune diseases and cancer.

Via Talk Markets

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2023

August 02, 2023

Via ACCESSWIRE

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com